103¦~6¤ë¸¹ ¹D ªk ªk °T (266)

DEEP & FAR

 

 

¬ÛÃöªºªk°|§P¨M

 

 ³ëÃü ±M§Q¤uµ{®v

¡EªFµØ¤j¾Ç¥Í©R¬ì¾Ç¨t

¡E²MµØ¤j¾Çµ²ºc¥Íª«»P¥Íª«¸ê°T©Ò

¡E»O¥_¬ì§Þ¤j¾Ç¹q¤l¤uµ{¾Çµ{

¡E¥xÆW¬ì§Þ¤j¾Ç±M§Q©Ò

 

Sunovion Pharma., Inc. v. Teva Pharms. USA, Inc. (Fed. Cir. Sept. 26, 2013)
(¨µ°jªk°|ªk©xLourie¡BSchall¤ÎReyna¥D«ù¡F·N¨£®Ñ¡GLourie)(¥ÑD.N.J., Wigenton, J. ¤W¶D)
¨tª§ÃĪ«²£«~»P±M§Q¡G¾|¥§´µ¶ð(Lunesta®)¡F¬ü°ê±M§Q6,44,673¸¹(¡¦673¸¹±M§Q)

®×¥ó¥»½è¤Î·í«eª§ÂI¡GSunovion¤½¥q¹ï¦a¤èªk°|±Â¤©¤£«IÅv²©ö§P¨Mªº·N¨£¡A´£¥X¤W¶D¡C¡¦673¸¹±M§Q«ü¦V¤@ºØ¥ª«¬¦õ¤Ç§J¶©(eszopiclone)[1]³æÃè¹³²§ºcª«ÃĪ«²Õ¦Xª«¡A¥ª«¬¦õ¤Ç§J¶©¬O½Ð¨D¶µ¤¤´¦ÅSªº¤Æ¾Ç¤Æ¦Xª«ªº¥ª«¬Ãè¹³²§ºcª«¡A¥¦¦b¥~®ø±Ûªº§Î¦¡¤U«h³QºÙ¬°¦õ¤Ç§J¶©(zopiclone)¡CÁp¨¹ÃĪ«­¹«~ºÞ²z§½­n¨D¨C¤@¿õ¾|¥§´µ¶ð¥]§t¤£¦h©ó(NMT)¦Ê¤À¤§0.3¥ª«¬¦õ¤Ç§J¶©©Ò¹ïÀ³ªº¥ª±ÛÃè¹³²§ºcª«¡A¥k«¬¦õ¤Ç§J¶©¡C¦a¤èªk°|±N¨ä§P¨M³¡¤À°ò©ó©Ò¥D±iªº½Ð¨D¶µ¤¤¡u°ò¥»¤W¨S¦³¡vªº­­¨îªº¥Î»y¸ÑÄÀ¤Î¹p­}³Õ¤h¹ï¥¦À³¸Ó­n¿í¦u¥¦ªº¤º³¡¥Í²£·Ç«hªº«OÃÒ¬°«e´£¡A¦a¤èªk°|¸ÑÄÀ¸Ó¥Î»y¡u°ò¥»¤W¨S¦³¡v·N«ü¡u¤Ö©ó¦Ê¤À¤§0.25ªº¥ª±Û²§ºcª«¡v¡C¦b¤W¶D¤¤¡ASunovion¤½¥q¥D±i¸Ó½Ð¨D¶µ­­¨îÀ³¬°¡u¥D­n¬O¡A¦ý¤£§¹¥þ¨S¦³¥ª±Û²§ºcª«¡A¨ä¥]§t¤j©ó¥ª¤Ç§J¶©Á`­«¬ù¦Ê¤À¤§90­«¶qªº¥k±Û²§ºcª«¡v¡CÁp¨¹¨µ°jªk°|»é¦^Sunovion¤½¥qªº¸ÑÄÀ¡C¸Ó³N»y¡u°ò¥»¤W¨S¦³¡v¶È¥X²{¦b½Ð¨D¶µ¤¤¡A¦Ó¥¼¥X²{¦b®Ñ­±±Ô­z¤¤ªº¥ô¦ó¦a¤è¡A¦ý¦b¥Ó½Ð¹Lµ{¤¤¡A¬°¤F§JªAÅã¦Ó©ö¨£©Ê®Ö»é¡A¥Ó½Ð¤H«ü¥X½d¨Ò1¡A¤Î§e°e¦@¦Pµo©ú¤H³¯­z¡u¦p©Ò­z½d¨Ò1¡vªº¥ª¤Ç§J¶©ªº¥k±Û²§ºcª«¡u¯Âºé«¬¡v¥]§t¡u§C©ó¦Ê¤À¤§0.25ªº¥k±Û²§ºcª«¡vªº«Å»}®Ñ¡C°ò©ó¥Ó½Ð¹Lµ{´Á¶¡ªº¨º¨Ç³¯­z¤Î¨ä¥L¸ê®Æ¡AÁp¨¹¨µ°jªk°|½T»{¤F¦a¤èªk°|ªº¸ÑÄÀ¡C¾¨ºÞ½T»{¤F¸Ó¸ÑÄÀ¡AÁp¨¹¨µ°jªk°|±À½¤F¦a¤èªk°|ªº¤£«IÅvªºµô¨M¡C

 

«ÝÄò

 



[1] ¦bÃĪ«¾Ç¦W©Î¬OÃĪ«¤Æ¾Ç¦W«e­±¥[¤WS-¡A¤¤¤å½°µ¥ª¦¡-©Î¬O¥ª«¬-¡A©M¥ª±Û-¤£¦P¡A¹³¬O±`¨£ªº¥ª±ÛC¨ä¹ê¤£¬O¥ª±Û¦Ó¬O¥ª«¬¡A¥ª±ÛC¬O»~ºÙ¡C¥ª«¬²§ºcª«±`±`¦bÃĪ«­ì¥»¾Ç¦Wªº«e­±¥[¤Wes¡C